相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Mass General Brigham has initiated two prospective clinical trials to evaluate Haystack MRD, a highly sensitive circulating tumor DNA test, for guiding postoperative treatment decisions in cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma. - The trials aim to investigate the clinical utility of this minimally invasive liquid biopsy technology for risk stratification and early detection of residual disease in cancer types that currently lack robust monitoring options. - Previous research published in The New England Journal of Medicine demonstrated that Haystack MRD identified clinical complete response at a median of 1.4 months compared to over six months using traditional imaging methods. - The collaboration between Haystack Oncology, a Quest Diagnostics subsidiary, and renowned cancer centers represents a significant step toward personalized, proactive cancer care through molecular monitoring.
- A groundbreaking Phase I/II clinical trial demonstrates 93% manufacturing success rate for Cultivated Autologous Limbal Epithelial Cell (CALEC) transplantation, offering new hope for limbal stem cell deficiency patients. - The therapy showed remarkable efficacy with 92% of patients achieving complete or partial success at 18 months post-transplantation, with significant improvements in corneal surface integrity and symptom reduction. - CALEC demonstrated an excellent safety profile with only one primary safety event reported, positioning it as a promising FDA-compliant treatment option for both mild and severe LSCD cases.
